anti vitronectin 65 75 (Santa Cruz Biotechnology)
Structured Review

Anti Vitronectin 65 75, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+vitronectin+65+75/Vitronectin+65%2F75+Antibody/bio_rxiv__64898__2026__01__14__699461-61-121-125
Average 93 stars, based on 21 article reviews
Images
1) Product Images from "Vitronectin defines a differentiation-restraining extracellular matrix state in myogenic cells"
Article Title: Vitronectin defines a differentiation-restraining extracellular matrix state in myogenic cells
Journal: bioRxiv
doi: 10.64898/2026.01.14.699461
Figure Legend Snippet: a, Immunoblot analysis of VN protein levels in fetal bovine serum, adult bovine serum, and adult horse serum. b, Immunoblot analysis of VN protein on day 0 (d0; before differentiation induction), day 1, and day 3 (d1 and d3; 1 and 3 day after differentiation induction). c, Representative immunofluorescence images showing the level and localization of VN protein in growth medium (GM) and day 1 in differentiation medium (DM). d, qPCR analysis for transcription of VN gene on d0, d1, and d3 after differentiation induction (n = 3). e, Immunoblot analysis for confirmation of immunodepleting of vitronectin from FBS. Vitronectin was depleted from FBS using control and anti-vitronectin antibody immobilized on Protein A Sepharose. f, Quantification of the inhibitory effect on myoblast differentiation with control and VN-immunodepleted FBS by immunofluorescence for MHC. (Control FBS: n = 1688, VN-reduced FBS: n = 1663 in counted nuclei number). g, Representative phase-contrast images of C2C12 cells cultured in GM, DM, and a serum-free DA-X medium supplemented with LIF on plates coated with or without VN coating. Images were captured on day 5 in each condition. Scale bar: 100 µm. Data are presented as mean ± s.d. Statistical significance was determined using one-way ANOVA in d and Student’s t-test in f ; * p < 0.05 .
Techniques Used: Western Blot, Immunofluorescence, Control, Cell Culture
Related Articles
Western Blot:Article Title: Vitronectin defines a differentiation-restraining extracellular matrix state in myogenic cells Article Snippet: As a first antibody, Anti-MyoD (5.8A, 1:5000; Novus Biologicals, NB100-56511), anti-Myogenin (1:10000; Abcam, ab124800), Anti-MHC (MF20, 1:5000; R&D Systems, MAB4470), Anti-β-Actin (C4, 1:5000; Santa Cruz, sc-47778), Anti-Stat3 (D3Z2G, 1:5000; Cell Signaling Technology, #12640), Anti-phospho-Stat3 (Tyr705, D3A7, 1:5000; Cell Signaling Technology, #9145), Anti-ERK1/2 (C-9, 1:5000; Santa Cruz, sc-514302), Anti-phospho-ERK (E-4, 1:5000; Santa Cruz, sc-7383), Anti-p38α/β MAPK (A-12, 1:5000; Santa Cruz, sc-7972), anti-phospho-p38 (E-1, 1:5000; Santa Cruz, sc-166182), Anti-p21 Waf/Cip1 (F-5, 1:5000; Santa Cruz, sc-6246), Anti-p27 Kip2 (F-8, 1:5000; Santa Cruz, sc-1641), Anti-FGF Receptor 1 (D8E4, 1:5000; Cell Signaling Technology, #9740), Anti-p-FGF Receptor 1 (Try653/654) (D4X3D, 1:5000; Cell Signaling Technology, #52928), Anti-Insulin Receptor β (4B8, 1:5000; Cell Signaling Technology, #3025), Anti-p-IGF-1 Receptor β (Tyr1135/1136)/Insulin Receptor β (Try1150/1151) (19H7, 1:5000; Cell Signaling Technology, #3024), Anti-Vitronectin 65/75 (D-8, Immunofluorescence:Article Title: Vitronectin defines a differentiation-restraining extracellular matrix state in myogenic cells Article Snippet: As a first antibody, Anti-MyoD (5.8A, 1:5000; Novus Biologicals, NB100-56511), anti-Myogenin (1:10000; Abcam, ab124800), Anti-MHC (MF20, 1:5000; R&D Systems, MAB4470), Anti-β-Actin (C4, 1:5000; Santa Cruz, sc-47778), Anti-Stat3 (D3Z2G, 1:5000; Cell Signaling Technology, #12640), Anti-phospho-Stat3 (Tyr705, D3A7, 1:5000; Cell Signaling Technology, #9145), Anti-ERK1/2 (C-9, 1:5000; Santa Cruz, sc-514302), Anti-phospho-ERK (E-4, 1:5000; Santa Cruz, sc-7383), Anti-p38α/β MAPK (A-12, 1:5000; Santa Cruz, sc-7972), anti-phospho-p38 (E-1, 1:5000; Santa Cruz, sc-166182), Anti-p21 Waf/Cip1 (F-5, 1:5000; Santa Cruz, sc-6246), Anti-p27 Kip2 (F-8, 1:5000; Santa Cruz, sc-1641), Anti-FGF Receptor 1 (D8E4, 1:5000; Cell Signaling Technology, #9740), Anti-p-FGF Receptor 1 (Try653/654) (D4X3D, 1:5000; Cell Signaling Technology, #52928), Anti-Insulin Receptor β (4B8, 1:5000; Cell Signaling Technology, #3025), Anti-p-IGF-1 Receptor β (Tyr1135/1136)/Insulin Receptor β (Try1150/1151) (19H7, 1:5000; Cell Signaling Technology, #3024), Anti-Vitronectin 65/75 (D-8, Control:Article Title: Vitronectin defines a differentiation-restraining extracellular matrix state in myogenic cells Article Snippet: As a first antibody, Anti-MyoD (5.8A, 1:5000; Novus Biologicals, NB100-56511), anti-Myogenin (1:10000; Abcam, ab124800), Anti-MHC (MF20, 1:5000; R&D Systems, MAB4470), Anti-β-Actin (C4, 1:5000; Santa Cruz, sc-47778), Anti-Stat3 (D3Z2G, 1:5000; Cell Signaling Technology, #12640), Anti-phospho-Stat3 (Tyr705, D3A7, 1:5000; Cell Signaling Technology, #9145), Anti-ERK1/2 (C-9, 1:5000; Santa Cruz, sc-514302), Anti-phospho-ERK (E-4, 1:5000; Santa Cruz, sc-7383), Anti-p38α/β MAPK (A-12, 1:5000; Santa Cruz, sc-7972), anti-phospho-p38 (E-1, 1:5000; Santa Cruz, sc-166182), Anti-p21 Waf/Cip1 (F-5, 1:5000; Santa Cruz, sc-6246), Anti-p27 Kip2 (F-8, 1:5000; Santa Cruz, sc-1641), Anti-FGF Receptor 1 (D8E4, 1:5000; Cell Signaling Technology, #9740), Anti-p-FGF Receptor 1 (Try653/654) (D4X3D, 1:5000; Cell Signaling Technology, #52928), Anti-Insulin Receptor β (4B8, 1:5000; Cell Signaling Technology, #3025), Anti-p-IGF-1 Receptor β (Tyr1135/1136)/Insulin Receptor β (Try1150/1151) (19H7, 1:5000; Cell Signaling Technology, #3024), Anti-Vitronectin 65/75 (D-8, Cell Culture:Article Title: Vitronectin defines a differentiation-restraining extracellular matrix state in myogenic cells Article Snippet: As a first antibody, Anti-MyoD (5.8A, 1:5000; Novus Biologicals, NB100-56511), anti-Myogenin (1:10000; Abcam, ab124800), Anti-MHC (MF20, 1:5000; R&D Systems, MAB4470), Anti-β-Actin (C4, 1:5000; Santa Cruz, sc-47778), Anti-Stat3 (D3Z2G, 1:5000; Cell Signaling Technology, #12640), Anti-phospho-Stat3 (Tyr705, D3A7, 1:5000; Cell Signaling Technology, #9145), Anti-ERK1/2 (C-9, 1:5000; Santa Cruz, sc-514302), Anti-phospho-ERK (E-4, 1:5000; Santa Cruz, sc-7383), Anti-p38α/β MAPK (A-12, 1:5000; Santa Cruz, sc-7972), anti-phospho-p38 (E-1, 1:5000; Santa Cruz, sc-166182), Anti-p21 Waf/Cip1 (F-5, 1:5000; Santa Cruz, sc-6246), Anti-p27 Kip2 (F-8, 1:5000; Santa Cruz, sc-1641), Anti-FGF Receptor 1 (D8E4, 1:5000; Cell Signaling Technology, #9740), Anti-p-FGF Receptor 1 (Try653/654) (D4X3D, 1:5000; Cell Signaling Technology, #52928), Anti-Insulin Receptor β (4B8, 1:5000; Cell Signaling Technology, #3025), Anti-p-IGF-1 Receptor β (Tyr1135/1136)/Insulin Receptor β (Try1150/1151) (19H7, 1:5000; Cell Signaling Technology, #3024), Anti-Vitronectin 65/75 (D-8, |
